Objective. Complement activation has been shown to occur in patients with juvenile rheumatoid arthritis (JRA). Since the two pathways of complement are activated by different stimuli (the alternate pathway by microbial products and IgA, and the classical pathway by immune complexes), we decided to study the relative contribution of the two pathways of complement activation in patients with JRA.
Juvenile rheumatoid arthritis (JRA) is a chronic systemic lar type of disease, and at normal levels in pauciarticular disease. Another study [5] reported that both classical inflammatory disease of childhood. It is classified into and alternative complement activation fragments are three subtypes, based on disease pattern in the first elevated in children with polyarticular and pauciarticular 6 months after onset: the pauciarticular, the polyarticudiseases, especially in children with active disease; howlar and the systemic-onset type. Even though immune ever, the relative contribution of the two pathways was complexes have been found in blood and synovial fluid not analysed. Both these pathways converge to a in all forms of JRA, the role of complement activation common pathway which leads to the generation of in the pathogenesis of the disease remains unresolved. membrane terminal attack complex ( TAC ). The TAC Studies on complement pathway activation in patients exists in two forms: the membrane-bound form which with JRA have shown conflicting results. Initial studies can be found on cells and tissues, and the fluid phase showed that the total haemolytic complement activity sC5-9 complex which can be detected in body fluids. and the levels of complement components C3 and C4
Changes in the TAC have been studied in only a few were normal in patients with JRA [1] [2] [3] . Later, measurepatients with JRA [4] . ment of complement activation products C3c, C3dg and
The classical and alternate pathways are activated by C4a in plasma and synovial fluid of patients with JRA different stimuli, and studying their relative contribution revealed variable results [1] [2] [3] [4] [5] [6] . Miller et al. [1] found to complement activation may give a clue to the possible levels of serum complement degradation products C3d initiating agents. Also, since the tissue damage is mediand C3a to be elevated in the systemic and polyarticuated by TAC, it may be pertinent to measure the level of this complement product. We therefore studied the The mean age of patients was 13.0 ± 5.0 yr (range morning stiffness, number of active joints, presence of 4.0-18.0 yr) and the mean duration of disease was systemic manifestations like fever, rash, hepatospleno-3.5 ± 1.5 yr (range 0.3-8.0 yr). Of the 56 patients megaly, lymphadenopathy) and clinical course were studied, 22 had polyarticular onset, 21 had systemic recorded. In addition, current medications were also onset and 13 had pauciarticular onset type of disease. recorded. The erythrocyte sedimentation rate (ESR) and
The disease was active in 51 patients and inactive in five concentration of haemoglobin and C-reactive protein patients. Fifty-four patients were receiving non-steroidal (CRP) were measured as laboratory parameters of disanti-inflammatory drugs and 14 were also receiving ease activity. Active disease was defined as the presence weekly oral low-dose methotrexate. of systemic manifestations and/or of active synovitis
Of the 56 patients, C3 and C4 levels were decreased (tenderness/synovial effusion/early morning stiffin one patient each. The levels of the complement ness >30 min) in at least three joints (for polyarticular degradation products, C4d, factor Bb and sC5-9 comdisease) and at least one joint (for pauciarticular disease) plex, were higher in patients as compared with controls in association with elevated CRP (>1.2 mg/dl ) or ESR (P < 0.01). The C4d levels were increased in only 17 (>25mm fall in first hour). All patients were carefully patients, whereas levels of factor Bb were elevated in 44 screened for any infection in the preceding 4 weeks and, patients and those of sC5-9 complex were increased in if there was any doubt, the patient was excluded from 51 patients. There was a trend towards higher levels of the study. In three patients three samples each, and in C4d, Bb and sC5-9 in polyarticular and systemic-onset seven patients two samples each, were collected at subsets of JRA, but it was not statistically significant, different time points. Plasma samples from 18 sexprobably due to the small number of patients in each matched young healthy controls, including eight chilgroup ( Table 1) . dren, were used as controls.
Among the patients with elevated sC5-9, only three For complement studies, blood was collected in EDTA had elevated C4d alone, 28 had elevation of factor Bb and transported on ice to the laboratory. Plasma was alone, whereas in 14 both C4d and factor Bb were separated and then stored at −70°C until analysis.
elevated. In six patients with elevated sC5-9, both C4d Levels of C3 and C4 were measured by a turbidimetric and factor Bb were normal. The value of Bb and sC5-9 method using anti-C3c and anti-C4 antibodies (Behring, had a linear correlation (r = 0.747, P < 0.01) (Fig. 1) , Germany). Concentrations of complement degradation while there was no significant correlation between C4d products (C4d, factor Bb and sC5-9 complex) were and sC5-9 levels (r = 0.36, P > 0.05). In addition, there measured by enzyme-linked immunosorbent assays was no significant correlation (r = 0.167) between C4d ( EIA) (Quidel Corporation, San Diego, CA, USA).
and factor Bb. The C4d level was used as a measure of activation of In 10 patients, for whom two or three serial samples the classical pathway, whereas factor Bb levels reflected were tested, there was a direct relationship between the activation of the alternate pathway. The sC5-9 levels levels of factor Bb and sC5-9; a rise in one was associated are a measure of the amount of the TAC generated as with a rise in the other (Fig. 2) , whereas the levels of a result of activation of the common pathway by either C4d had no such relationship with sC5-9 levels. the classical or alternate pathway and is thus a sensitive indicator of overall complement activation.
Discussion
In brief, test plasma specimens in appropriate dilution were added to EIA wells coated with monoclonal antiOur data show that sC5-9 levels are elevated in a body to the respective complement product and incubmajority of patients with JRA. This indicates that the ated for 1 h. After washing, a second antibody complement pathway is activated in these patients, conjugated with horseradish peroxidase was added. This resulting in the formation of membrane TAC. Activation was followed by the addition of tetra methyl benzadine of the complement pathway has previously been shown ( TMB) substrate; the reaction was stopped after 15 min to occur [1, 3, 5, 6 ]; however, the formation of memand the absorbance read at 450 nm. For each analyte, brane TAC has been rarely reported. Our data may thus concentrations in the test samples were read from a provide more conclusive evidence for the pathogenetic standard plot between absorbance and concentration of significance of complement pathway activation in JRA. a set of standards. Values above the mean ± 2 .. of
The exact site of membrane TAC generation is not normal healthy controls were taken as abnormal.
known and could be synovium, skin (in systemic onset) or spleen.
Statistical analysis
Complement activation can occur by the classical or the alternate pathway, or by a combination of the two. Pearson's correlation coefficient was used to study the relationship of various continuous variables with one Our data suggest that the alternate pathway is the major contributor in patients with JRA, with a minor contribution by the classical pathway. Activation of the classical pathway has been reported to occur in polyarticular, systemic-onset disease [1, 5] and pauciarticular-onset disease [3, 5] . Higher levels of C4d in systemic-onset disease could suggest that in this variant more IgG-and IgM-containing immune complexes are generated which cause classical pathway activation.
Activation of the alternate pathway found by us was also present in the study reported by Jarvis et al. [5] , but in that study patients with systemic-onset disease were not included. Thus, our study is the first report of alternate pathway activation in systemic-onset disease. The presence of alternate pathway activation in threequarters of patients suggests that it may have a role in disease pathogenesis. In a recent study [6 ] , levels of of circulating immune complexes than levels of C4d, implying that immune complexes were activating the alternate pathway.
Alternate pathway activation can occur by immune complexes bearing IgA rheumatoid factor (RF ). Indeed, high-molecular-weight IgA RF-containing immune complexes have been described in children with polyarticular disease [8] . The alternate pathway is also the major mechanism of solubilization of large preformed aggregates [9] , and there may be some immune complexes preformed in the tissues in patients with JRA which can activate the alternate pathway when they reach the circulation. In addition, bacterial products can activate the alternate pathway. Analysis of immune complexes from patients with JRA have revealed novel 40 and 60 kDa bands which are resistant to DNase, RNase and proteases, suggesting that these may be lipopolysaccharide-enterobacterial protein complexes, glycosaminoglycans or some as yet unknown compounds [10] . In contrast, in 1990, Olds and Miller [3] failed to show the presence of antibodies to streptococcal cell wall peptidoglycan-polysaccharide polymers in the immune complexes isolated from patients with JRA, indirectly showing that these antigens are not present in immune complexes of patients with JRA. Rarely, a low level of C3b generated from activation of the classical pathway can perpetuate activation of the alternate pathway.
In addition, there may be some inhibitors of classical the immune complexes and thus prevent the classical represents sC5-9 complex levels (mg/ml ). On the x-axis, the time in months represents time since inclusion in the study.
pathway activation [11] . 
